XL-protein: the PASylation company
  • About
    • Corporate overview
    • Corporate strategy
    • Leadership team
  • Technology
    • Technology
    • PAS-Advantages
    • Intellectual property
  • Partnering
    • Partnering
  • News and Publications
    • Press Releases
    • Receive our Press Releases
    • Partner’s Press Releases
    • Key publications
    • Various publications
  • Careers
  • Contact
    • Contact
    • Imprint
    • Disclaimer
    • Privacy Policy
  • Search
  • Menu Menu

XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure using PASylation® Technology

15. October 2020/in News /by web28627236

SAN DIEGO, U.S.A., and FREISING, Germany, 15th October, 2020: Antlia Bioscience, Inc., a privately owned biopharmaceutical company located in San Diego, California, and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, are pleased to announce a Strategic Alliance using XL-protein’s proprietary PASylation® technology for plasma half-life extension to develop a novel, long-acting, peptide therapeutic treatment for chronic heart failure. […]

Read more
http://xl-protein.com/wordpress/wp-content/uploads/2016/09/XLmlogo3.png 0 0 web28627236 http://xl-protein.com/wordpress/wp-content/uploads/2016/09/XLmlogo3.png web286272362020-10-15 19:02:002020-10-16 10:48:25XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure using PASylation® Technology

XL-protein and DNX Biopharmaceuticals Announce Collaboration to Develop Novel Inflammasome-Directed Therapeutics using PASylation® Technology

25. February 2020/in News /by web28627236

Freising, Germany and San Diego, CA, February 25, 2020 — XL-protein has extended its existing partnership with DNX Biopharmaceuticals, a biopharmaceutical company developing nonimmunogenic, long-acting therapeutic proteins for the treatment of patients with life-long diseases, to develop novel inflammasome-directed therapeutics for the treatment of diseases linked to inflammation, autoinflammation and oncology. DNX has exercised an […]

Read more
http://xl-protein.com/wordpress/wp-content/uploads/2016/09/XLmlogo3.png 0 0 web28627236 http://xl-protein.com/wordpress/wp-content/uploads/2016/09/XLmlogo3.png web286272362020-02-25 13:08:022020-02-25 15:59:48XL-protein and DNX Biopharmaceuticals Announce Collaboration to Develop Novel Inflammasome-Directed Therapeutics using PASylation® Technology

Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform

18. December 2018/in News /by web28627236

SAN DIEGO, U.S.A., and FREISING, Germany, 18th December, 2018: Ajinomoto Bio-Pharma Services, a fully owned subsidiary of Ajinomoto Co. Inc. (TSE: 2802), and XL-protein GmbH, a privately owned German biopharmaceutical company, are pleased to announce a Strategic Alliance. Ajinomoto will apply its proprietary Corynex® expression system together with XL-protein’s proprietary PASylation® technology for plasma half-life […]

Read more
http://xl-protein.com/wordpress/wp-content/uploads/2016/09/XLmlogo3.png 0 0 web28627236 http://xl-protein.com/wordpress/wp-content/uploads/2016/09/XLmlogo3.png web286272362018-12-18 18:08:342018-12-18 18:11:25Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform
Page 1 of 8123›»

Latest News:

  • XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure using PASylation® Technology 15. October 2020
  • XL-protein and DNX Biopharmaceuticals Announce Collaboration to Develop Novel Inflammasome-Directed Therapeutics using PASylation® Technology 25. February 2020
  • DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson 18. February 2020

Archives

  • October 2020
  • February 2020
  • January 2020
  • April 2019
  • December 2018
  • January 2018
  • November 2017
  • July 2017
  • November 2016
  • June 2016
  • February 2016
  • December 2015
  • June 2015
  • February 2015
  • October 2014
  • August 2013
  • June 2013
  • April 2013
  • October 2012
  • June 2012
  • September 2011
  • March 2011
  • January 2011
  • September 2009

Partnering contact:

XL-protein GmbH
Claus Schalper
Lise-Meitner-Str. 30
85354 Freising
Germany

Phone: +49 (0) 8161 53730-90
Fax: +49 (0) 8161 53730-99
E-mail: bd@xl-protein.com

Web: www.xl-protein.com

© 2020 - All Rights Reserved for XL-protein GmbH | Imprint | Disclaimer | Data Privacy Policy
  • Mail
Scroll to top